Intravenous Immunoglobulin Market Size is slated to gain remarkable traction over 2022-2028, as a result of the significant usage of IV immunoglobulin to increase platelet counts among patients with immune thrombocytopenic purpura, among other medical applications. Likewise, the high risks of neurological diseases among the increasing elderly population will also proliferate industry size, as intravenous immunoglobulin injection can prevent harmful antibodies from damaging the nerves. IVIg or intravenous immunoglobulin refers to products made of antibodies that are administered intravenously through the vein, mainly used for patients with antibody deficiencies. This therapy treatment is prepared from the blood of healthy donors to develop a super-concentrated and diverse range of antibodies against infectious organisms in the body.
Increase in infectious disease outbreaks and the rising prevalence of autoimmune diseases among elderly people will foster intravenous immunoglobulin market trends during the forecast period. In autoimmune conditions like lupus, for example, the IVIg treatment can raise red blood counts, thus reducing common symptoms like anemia and tiredness. Such product benefits, along with the mounting number of people with hemophilia in the U.S., will stimulate the deployment of IVIg injection, as it can be used as second-line therapy for hemophilia patients who do not respond to immunosuppression. However, the side-effects associated with the use of IVIg, including allergic reaction and difficulty breathing, may create a hindrance to the steady market growth during the estimated timeline.
With regards to application, the bone marrow transplant segment is anticipated to hold an appreciable share in the intravenous immunoglobulin industry by 2028. This is due to the surging patient population with cancer and the growing reliance on this medical procedure to treat patients with other diseases like anemia and immune deficiency disorders. Furthermore, the capability of intravenous immunoglobulin therapy to treat pneumonia caused by cytomegalovirus after the bone marrow transplant procedure will bolster the overall market expansion in the years ahead.
Europe intravenous immunoglobulin market is poised to depict a strong growth rate through 2028. This growth is on account of the rising investment interest towards healthcare infrastructure and the implementation of new hospital building programs in the UK. In addition, the high burden of immunodeficiency diseases like HIV among mid-age adults in countries like England is likely to contribute to the growing popularity of the IVIg treatment to fight against viral infections.
Prominent intravenous immunoglobulin market players include Hualan Biological Engineering Inc., ADMA Biologics, BioScrip, Inc., China Biologic Products, Inc., Takeda Pharmaceutical Company Limited, Biotest AG (Tiancheng International Investment Limited), Shanghai RAAS Blood Products Co., Sanquin, LFB Biomedicaments, Kedrion S.p.A., Bio Products Laboratory, Shire plc (Takeda Pharmaceutical Company), Talecris, Octapharma, Grifols, CSL Behring, and Baxter Healthcare, among others. These companies are focusing on innovative product launches to strengthen their footprint in the global market. For instance, in July 2021, Octapharma USA received the U.S. FDA approval for Octagam 10%, its first intravenous immunoglobulin to be indicated for the treatment of the immune-mediated inflammatory disease known as dermatomyositis in adults.
Apart from the economic crisis, COVID-19 has posed significant challenges for patients with mental and neurological conditions, given their heightened vulnerability to the infection. Among the younger population, a rare but serious condition of MIS-C (multi-system inflammatory syndrome) has also been reported across several regions. Factors such as these have influenced various medical experts to evaluate the effectiveness of IVIg injection for COVID-19 patients. Leading plasma-derived medicine provider, Grifols, for example, announced plans to participate in an international study through a collaboration with the NIH and NIAID in April 2021, to examine an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients, thus contributing to intravenous immunoglobulin market dynamics over the foreseeable future.
Market, by Application
Market, by End-Use
The above information is provided for the following regions and countries: